|
Medicare to Cover Edwards’ TAVR, Company Adjusts Sales Forecast
U.S. sales of Edwards’ Sapien transcatheter aortic valve replacement (TAVR) could reach as high as $240 million in 2012, buoyed by a federal decision that Medicare will pay for the medical device, effective immediately.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives